Interim report, January – March 2005
First quarter 2005 Acquisition of Cibacen and Cibadrex, pharmaceuticals from Novartis, enhanced sales and profit. Group sales jumped 45% to SEK 394 million (271). Operating profit increased to SEK 109.3 million (34.3). Profit after tax soared to SEK 68.9 million (23.3). Profit per share increased to SEK 6.29 million (2.32). Highlights and forecast for 2005 New share issue worth SEK 569 million: oversubscribed by 74%. Establishment on new markets. Proposal for a split: five new shares for one old share. Increased forecast: Operating profit for the year 2005 expected to reach